tiakis Biotech

Tiakis Biotech is a private, clinical-stage biotech company headquartered in Kiel, Germany, founded in 2000 (with a noted 2020 date in some records, suggesting a corporate restructuring). The company is developing Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug based on the human protein Elafin, targeting Pulmonary Arterial Hypertension and postoperative inflammatory complications. With a leadership team boasting multi-disciplinary experience and support from government R&D programs, Tiakis aims to shift treatment paradigms towards preventive, root-cause focused therapies. The company is currently pre-revenue, advancing its lead candidate through clinical development.

Platform based on the endogenous tissue-protective protein Elafin (PI3), a serine protease inhibitor, harnessed for its anti-inflammatory and organ-protective properties.

In PAH, Tiakis faces competition from both existing vasodilator therapies and a new wave of investigational drugs targeting inflammation, fibrosis, and metabolism. In postoperative care, it must demonstrate superiority over standard supportive care and compete with other agents in development for preventing organ injury.